US › Healthcare

Silence Therapeutics PLC (SLN)

US · Healthcare · Biotechnology

$11.17+4.59%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$421,292
Revenue YoY
+129.3%
Net profit
$-14.9M
Profit YoY
+59.5%
EPS
$-0.33
EPS estimate
$-0.23
Net margin
-3,544.3%

EPS came in at -0.33 against a street estimate of -0.23 — a miss of 44.4%.

Key statistics

Market cap
$504.5M
Forward P/E
0.0
P/B
10.03
Book value
$1.05
EPS (TTM)
$-1.62
52-week high
$12.19
52-week low
$4.19
50-day MA
$8.75
200-day MA
$6.85
Beta
1.41

Analyst view

Analysts rate Silence Therapeutics PLC a buy (6 buy, 0 hold, 1 sell out of 7) with an average price target of $29.17.

Shareholding

Insiders
21.77%
Institutions
44.55%

Largest institutional holders

FundStake
TCG Crossover Management, LLC6.42%
Siren, L.L.C.6.16%
Redmile Group, LLC4.58%
Nantahala Capital Management, LLC4.54%
Citadel Advisors Llc2.61%
Millennium Management LLC2.27%
Great Point Partners LLC2.16%
Nextech Invest, Ltd.2.02%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Silence Therapeutics PLC — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.